Cormedix Inc. 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on September 20, 2012, and September 21, 2012. Cormedix Inc., a Delaware corporation, reported the initial closing of a private placement financing and an extension of its compliance plan with the NYSE Amex.
Key Financial Metrics and Transaction Details
- Financing Structure: The Company sold Units consisting of 9% Senior Convertible Notes (maturity September 20, 2013) and five-year redeemable Warrants.
- Initial Closing Proceeds: 850 Units were sold for a gross amount of $850,000.
- Net Proceeds: $770,000 was funded to the Company after fees.
- Placement Agent Fees: $62,500 in cash and warrants to purchase 212,500 shares of common stock.
- Offering Capacity: The offering is structured as "all-or-none" for the first 500 Units ($500,000) and "reasonable efforts" for up to 2,500 additional Units, with a maximum potential raise of $3,000,000.
- Use of Proceeds: Marketing, manufacturing, rent, utilities, licensing, payroll, working capital, and general corporate purposes.
Material Changes and Listing Status
The filing details a significant change in the Company's listing status on the NYSE Amex. The Company had previously received notice of non-compliance due to substantial losses and impaired financial condition. While the exchange initially accepted a compliance plan with a deadline of August 22, 2012, the NYSE Amex granted an extension on September 21, 2012, moving the deadline to January 31, 2013. Failure to regain compliance by this new date could result in delisting.
Outlook, Risks, and Management Commentary
- Registration Rights: The Company agreed to file a registration statement for the resale of conversion shares within 60 days of the final closing and use commercially reasonable efforts to have it declared effective within 120 days.
- Liquidated Damages: If the Company fails to meet registration obligations, it must pay 1.0% of the purchase price per month, capped at 5% of the aggregate principal amount of the Notes.
- Prepayment Terms: The Company may prepay Notes by paying 120% of the principal and accrued interest, subject to share ownership limitations.
- Warrant Redemption: The Company may redeem Warrants for $0.001 per warrant if the stock price exceeds 140% of the exercise price ($0.40) for ten consecutive trading days and volume requirements are met.
- Delisting Risk: The primary risk remains the potential delisting from NYSE Amex if the Company fails to meet the extended compliance deadline of January 31, 2013.
Investor Verification Checklist
- Verify the final closing date and total amount raised against the $3,000,000 maximum.
- Confirm the filing and effectiveness status of the registration statement for the resale of conversion shares.
- Monitor the Company's progress toward regaining NYSE Amex compliance by the January 31, 2013 deadline.
- Review the definitive Subscription Agreement for specific terms regarding the 120% prepayment penalty and warrant redemption triggers.
- Check for any subsequent filings regarding the participation of officers and directors as Purchasers in the offering.